Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — Shareholder Meeting (July 2021)
38 slides from Anteris Technologies Global's shareholder meeting presentation, Jul 15, 2021
Slide 1: Anteris Technologies Ltd Annual General Meeting 2020
Anteris Technologies Ltd Annual General Meeting 2020 CEO Presentation 15 July 2021
Slide 2: Disclaimer
Disclaimer This presentation contains general information which is current as of 15 July 2021. It is information given in summary form and does not purport to be complete. Information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not ta
Slide 3: DurAVR for lifetime management of Aortic Stenosis patients
DurAVR™ for lifetime management of Aortic Stenosis patients www.anteristech.com | Follow us @anteristech Copyright Anteris Technologies Ltd 2021
Slide 4: 2020 was an incredible year of progress, milestones and value creation
2020 was an incredible year of progress, milestones and value creation 2020 is the year DurAVR™ moved from concept to product • Commenced FIH DurAVR™ study • “Best Innovation” awarded at PCR London Valves • Developed unique commissure attachment method to enhance stress reduction • Finalized specifi
Slide 5: Financial highlights 2020
Financial highlights 2020 UP TO $11.9M $20M 36% Sales revenue and Funding package Reduction in Selling, other income announced in early General and Administrative 2021 expenses compared to prior year $2.3M 43.1 Capital raised in Total full time 2020 Equivalent staff
Slide 6: FY20 Financial information
FY20 Financial information $ million FY2019 FY2020 FY2020 budget actual • LeMaitre transaction in 2019 brought ADAPT® revenue 10.2 6.8 6.2 forward revenue/capital as well as Infusion revenue 6.9 - 0.9 reduced SG&A 17.1 6.8 7.1 • Ongoing 20% margin over costs Gain on business divestments 24.9 - - • O
Slide 7: Breakdown of operational results
Breakdown of operational results Overall results $15.3M loss Research & Development $11.1M Corporate & Operational $4.2M • DurAVRTM valve development • Regulatory and Medical program • Capital raising costs • First-in-human trials • Company compliance costs • Design of the TAVR delivery • Insurance
Slide 8: Patent applications increased dramatically in 2020
Due to the pace of development in 2020 patent applications increased dramatically In 2020, Anteris: - 38 new applications throughout the world in 7 different patent families Filed - Received 2 issued patents (5% of pending applications) - Received 1 notice of allowance in the United States
Slide 9: Progress since code red - Our ability to pivot has been key
Progress since code red - Our ability to pivot has been key Code Red Objectives Where we’re at today • Manufacturing pass rates to rise from a low of 22% to 75+% • Manufacturing pass rates have been consistently >70% since FY17 with pass rates of 76% in FY20 • 250% increase in production output • Pr
Slide 10: Equity capital raised
Equity capital raised $40.0 M $35.8 M $35.4 M $35.0 M $30.0 M $25.0 M $20.0 M $18.4 M $18.3 M $15.0 M $14.1 M $10.0 M $5.0 M $3.9 M $1.1 M $0.0 M $0.0 M $0.0 M 2013 2014 2015 2016 2017 2018 2019 2020 2021
Slide 11: Capital raised through debt & equity
Capital raised through debt & equity $40.0 M Equity capital raised $5.0 M Borrowings $35.0 M LeMaitre & Infusion $30.0 M $25.0 M $20.0 M $35.8 M $35.4 M $15.0 M $28.2 M $10.0 M $18.4 M $18.3 M $14.1 M $5.0 M $5.0 M $5.0 M $1.2 M $3.9 M $1.0 M $1.1 M $0.0 M 2013 2014 2015 2016 2017 2018 2019 2020 202
Slide 12: AVR share price and trading volumes
AVR share price and trading volumes Small volumes and price declines Strong volumes and price growth Source: www.marketindex.com.au/asx/avr
Slide 13: What is this disease and why are we competitive?
What is this disease and why are we competitive?
Slide 14: Aortic Stenosis has a high mortality rate within 2-3 years if left untreated
Aortic Stenosis has a high mortality rate within 2-3 years if left untreatedvv • It is estimated that 1 in 8 elderly Australians has Aortic Stenosis (AS). • Calcific Aortic Stenosis is the most common cause of Aortic Stenosis. • While up to 1.5 million people in the US suffer from AS, approximately
Slide 15: Aortic stenosis is a disease of calcification
Aortic stenosis is a disease of calcification Calcium deposits cause a narrowing of the valve opening and an increase in pressure Calcium build up in valve with stenosis
Slide 16: Anteris is focused on tissue science and valve technology
Anteris is focused on tissue science and valve technology Three reasons Anteris will be the market leader in the future DurAVR™ is first and only 3D single- 1 piece aortic valve Clinically proven ADAPT® anti-calcification 2 treatment ACELLULARIZE DETOXIFY CROSSLINK DurAVR™ THV Delivery System for 3
Slide 17: What the experts are saying
ANTERIS What the experts are saying
Slide 18: Experts need a TAVR with better Hemodynamics & Durability
Experts need a TAVR with better Hemodynamics & Durability 5min
Slide 19: Anteris is supported by a world class TAVR focused advisory board
Anteris is supported by a world class TAVR focused advisory board Gorav Ailawadi, MD Vinayak Bapat, MD Samir Kapadia, MD University of Virginia Health System New York-Presbyterian/Columbia Medical Cleveland Clinic Charlottesville, VA Center, New York, NY Cleveland, OH Susheel Kodali, MD Christopher
Slide 20: Younger patients need new solutions
Younger patients need new solutions Younger patients need longer lasting next generation valve technology Patient Age Key Considerations Younger patients now eligible Guidelines What Life Expectancy TAVR as class(I) for ages 65-80 Does this Mean? Exercise Capacity Indications: • Moderate • Mean age
Slide 21: Current TAVR devices fall short in two critical areas
Current solutions attempt to address 4 key areas Current TAVR devices Current products fall short in two critical areas Predictable Optimal Low Incidence of Procedure Hemodynamic Durability Complications Performance Competitor products leave the patient in “mild” Competitor products can start to ste
Slide 22: DurAVR THV satisfies all key areas
DurAVR THV satisfies all 4 key areas ™ Current TAVR devices ComASUR™ delivery system is Better hemodynamics at rest DurAVR’s™ 3D uni-body design has more predictable with and during increased cardiac greater structural integrity + ADAPT® commissural alignment output (exercise) anticalcification trea
Slide 23: The Australian perspective
ANTERIS The Australian perspective mM | 12 2 ADAPT es for life
Slide 24: Slide 24
Slide 25: The Competitors
ANTERIS The Competitors
Slide 26: TAVR Market Shares by Region (US & EU5)
TAVR Market Shares by Region (US & EU5)
Slide 27: DurAVR better by design
DurAVR™ better by design Effective Orifice Area 3.0cm2 1.5 to 3 cm2 1.0 to 1.5 cm2 <1.0 cm2 (EOA) cm2 Mean Gradient 5 mmHg <20 mmHg 20-40 mmHg >40 mmHg mmHg Mean Gradient EOA cm2 mmHg *Sapien 3 19-16 mmHg 1.22-1.66 cm2 *Corevalve 8.27-14.43 mmHg 1.12-2.15 cm2 **DurAVR™ 5-7 mmHg 2.5-3 cm2 *Hahn et al
Slide 28: DurAVR THV System meets the needs of Patients and Physicians
DurAVR™ THV System meets the needs of Patients and Physicians PROVEN ADAPT® TISSUE PLATFORM BALLOON 3D SHAPED EXPANDABLE, VALVE LARGE CELL UNIBODY SUPRA- CONSTRUCT ANNULAR COMMISSURAL PVL SOLUTION ALIGNMENT BALLOON SELF EXPANDABLE EXPANDING MORE EFFICIENT MANUFACTURING PROCESSES LARGE CELL SUPRA ANN
Slide 29: DurAVR THV System designed to go the distance
DurAVR™ THV System designed to go the distance BALLOON SELF EXPANDABLE EXPANDING Predictable procedure Only 3D “unibody” valve Predictable procedure Larger EOA with superior hemodynamics Normal hemodynamics Low pacemaker rate ® Built with ADAPT proven anti-calcification tissue technology Advanced ti
Slide 30: The road ahead
The road ahead ANTERIS
Slide 31: 2021/2022 will be the most transformational in the company's history
2021/2022 will be the most transformational in the company’s history Discussions around DOCTORS & PATIENTS NEEDS: developing a Self Balloon Expandable with the Expanding or Balloon hemodynamics benefits of a Self- Expanding valve expandable heart valve Creation of Anteris’ CHOICE & TVT Transcatheter
Slide 32: Anteris pipeline is poised to drive major catalysts
Anteris pipeline is poised to drive major catalysts from 2021 Product Development Pre-Clinical Clinical Registration US (EFS, Pivotal), DurAVR™ THV Preclinical Studies EU (CE) Valve Replacement DurAVR™ SHV Programs FIH (stentless Aortic) DurAVR™ SHV POC (stented Aortic) DurAVR™ SHV POC Advancements
Slide 33: Shareholder questions
Shareholder questions Questions • When will you get a partnership? • When can we get the licence fee deal implied in the MST report? • If you need to go it alone how will you secure capital for this? • When raising capital why do retail holders not get an option to participate ? • Is Resilea a real
Slide 34: A great team in the right locations
A great team in the right locations Exceptional individuals doing exceptional things Biologics Manufacturing / R&D Innovation Centre & Corporate HQ Strategic Hub in Europe (Malaga, Australia) (Minneapolis, USA) (Geneva, Switzerland) Finance & IT Team (Brisbane, Australia)
Slide 35: Conclusions - We are now in the window of certainty
Conclusions - We are now in the window of certainty It’s been an incredible year of progress and achievement – we now have a very competitive product ready to enter its registration studies This is no longer a discussion about will we be able to develop a product, or if it’s competitive The risk cli
Slide 36: Mary is 68 years old and living with Aortic Stenosis
Mary is 68 years old and living with Aortic Stenosis • Her stenosis has become so severe, she is no longer able to do things she loves, such as going for long walks with her grandkids • Her doctor says she needs a new valve soon – otherwise she may not live too much longer • Recent approvals have ma
Slide 37: An Australian Global Health Care Company
Anteris An Australian Global Health Care Company
Slide 38: Innovation to support life's journey is at the heart of our story
Innovation to support life’s journey is at the heart of our story… North America Europe Australia 860 Blue Gentian Road, Suite 340 Rte de Pre-Bois 20, PO BOX 1877 Toowong Tower Level 3, 9 Sherwood Rd Eagan MN 55121 1215 Geneva 15 Toowong QLD 4066
Anteris Technologies — Shareholder Meeting (July 2021) on 6ix